US 2022/0010024 A1 · Anti-Human CD52 Immunoglobulins

Abstract

The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.

Claims24

Dependent claims

A monoclonal anti-human CD52 antibody or an antigen-binding portion thereof, wherein the light chain and heavy chain of said antibody comprise the three complementarity determining regions (CDRs) found in

a) SEQ ID NOs:
3 and 16, respectively;
b) SEQ ID NOs:
4 and 17, respectively;
c) SEQ ID NOs:
5 and 18, respectively;
d) SEQ ID NOs:
6 and 19, respectively;
e) SEQ ID NOs:
7 and 20, respectively;
f) SEQ ID NOs:
8 and 21, respectively;
g) SEQ ID NOs:
9 and 22, respectively;
h) SEQ ID NOs:
10 and 23, respectively;
i) SEQ ID NOs:
11 and 24, respectively;
j) SEQ ID NOs:
12 and 25, respectively;
k) SEQ ID NOs:
12 and 137, respectively;
or
l) SEQ ID NOs:
13 and 26, respectively.

22 more elements

Dependencies are inferred from the claim text.

Anti-Human CD52 Immunoglobulins

Life of this patent

Anti-Human CD52 Immunoglobulins

Life of this patent

Abstract

Claims24